Hepatic recovery after damage produced by sub-chronic intoxication with the cyanotoxin microcystin LR

Darío Andrinolo1, Daniela Sedan, Luis Telese

  • 1Centro de Investigación y Desarrollo en Criotecnología de Alimentos (CIDCA), Universidad Nacional de La Plata, La Plata, Argentina. dandrinolo@yahoo.com

Insights

Sub-chronic exposure to microcystin-LR (MC-LR) damages mouse liver and kidney tissues, increasing lipid peroxidation. However, hepatic tissue shows significant recovery potential after exposure cessation, though architectural repair remains incomplete.

Area of Science:

  • Toxicology
  • Hepatology
  • Environmental Health

Background:

  • Microcystin-LR (MC-LR) is a potent cyanotoxin with known hepatotoxic effects.
  • Sub-chronic exposure studies are crucial for understanding long-term health impacts and recovery.
  • Assessing tissue architecture, liver function, and oxidative stress provides a comprehensive view of MC-LR toxicity.

Purpose of the Study:

  • To investigate the effects of sub-chronic microcystin-LR (MC-LR) exposure on mouse liver and kidney.
  • To evaluate the recovery process of hepatic tissue following MC-LR administration.
  • To determine the impact of MC-LR on histological architecture, liver function, and lipid peroxidation.

Main Methods:

  • Mice received intraperitoneal injections of MC-LR (25 microg/kg) or saline every two days for one month.
  • Histopathological analysis examined liver tissue architecture and cellular changes.
  • Biochemical assays measured serum enzyme activities, hepatic lipid content, and lipid peroxidation levels in liver and kidney.

Main Results:

  • MC-LR exposure disrupted liver lobular architecture and induced cytoplasmic vacuoles.
  • Significant increases in hepatic lipid content and lipid peroxidation were observed in MC-LR treated mice.
  • Altered serum alkaline phosphatase and aspartate aminotransferase levels indicated liver damage.

Conclusions:

  • Hepatic tissue demonstrates a notable capacity for recovery from sub-chronic MC-LR induced damage at cellular and physiological levels.
  • While functional recovery is evident, complete restoration of liver lobular architecture may be incomplete.
  • The balance between damage and repair mechanisms is critical for determining toxicity outcomes and should inform risk assessments.

Related Concept Videos

Liver Regeneration01:24

Liver Regeneration

The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Toxic Reactions: Overview01:26

Toxic Reactions: Overview

When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...